Insulet Corporation Stock Price, News & Analysis (NASDAQ:PODD)

$70.64 1.64 (2.38 %)
(As of 11/18/2017 03:42 AM ET)
Previous Close$70.64
Today's Range$68.37 - $70.89
52-Week Range$32.12 - $72.26
Volume494,067 shs
Average Volume780,811 shs
Market Capitalization$4.21 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About Insulet Corporation (NASDAQ:PODD)

Insulet Corporation logoInsulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM). The Omnipod System features two discreet devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. The Omnipod System is a discreet two part design, the Omnipod device (Pod) and the PDM that eliminates the need for the external tubing required with conventional pumps. The Pod is a self-adhesive device that the patient fills with insulin and wears directly on the body.


Industry, Sector and Symbol:
  • Industry: Medical Prosthetics
  • Sub-Industry: Health Care Equipment
  • Sector: Medical Prosthetics
  • Symbol: NASDAQ:PODD
  • CUSIP: 45784P10
  • Web: www.myomnipod.com
Debt:
  • Debt-to-Equity Ratio: 4.65%
  • Current Ratio: 4.88%
  • Quick Ratio: 4.42%
Sales & Book Value:
  • Annual Sales: $366.99 million
  • Price / Sales: 11.20
  • Book Value: $1.28 per share
  • Price / Book: 55.19
Profitability:
  • Trailing EPS: ($0.50)
  • Net Income: ($28,870,000.00)
  • Net Margins: -6.66%
  • Return on Equity: -43.85%
  • Return on Assets: -6.26%
Misc:
  • Employees: 640
  • Outstanding Shares: 58,190,000
 

Frequently Asked Questions for Insulet Corporation (NASDAQ:PODD)

What is Insulet Corporation's stock symbol?

Insulet Corporation trades on the NASDAQ under the ticker symbol "PODD."

How were Insulet Corporation's earnings last quarter?

Insulet Corporation (NASDAQ:PODD) posted its quarterly earnings results on Thursday, November, 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.06. The medical instruments supplier had revenue of $121.80 million for the quarter, compared to the consensus estimate of $114.02 million. Insulet Corporation had a negative net margin of 6.66% and a negative return on equity of 43.85%. Insulet Corporation's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.05) earnings per share. View Insulet Corporation's Earnings History.

When will Insulet Corporation make its next earnings announcement?

Insulet Corporation is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Insulet Corporation.

Where is Insulet Corporation's stock going? Where will Insulet Corporation's stock price be in 2017?

15 brokerages have issued 12 month target prices for Insulet Corporation's shares. Their forecasts range from $44.00 to $74.00. On average, they anticipate Insulet Corporation's share price to reach $59.77 in the next year. View Analyst Ratings for Insulet Corporation.

What are Wall Street analysts saying about Insulet Corporation stock?

Here are some recent quotes from research analysts about Insulet Corporation stock:

  • 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (11/11/2017)
  • 2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
  • 3. Jefferies Group LLC analysts commented, "PODD's 4Q sales were $3mn above guidance with strength in all areas: US +17%, OUS +35%, and DD +34%. New patient starts in 2016 at +13% missed the +20% annual target reiterated just last Q. To this end, mgmt highlighted that a more important metric to pay attention to is the 15k total patient adds (vs. 13k in 2015) and the installed base grew by 15%. Despite 670G around the corner, Insulet remains largely dismissive of the launch." (2/28/2017)
  • 4. Wedbush analysts commented, " Insulet posted robust 4Q16 results and issued healthy 2017 guidance, signaling confidence in the overall growth of its diabetes and drug delivery franchises despite a more competitive diabetes landscape. PODD's relatively new management continues to fire on all cylinders with betterthan-expected revenues across all three of its business segments and solid gross margin expansion. The main takeaways from the quarter were continued strength within the company's diabetes franchises (US and OUS), the success of its drug delivery segment, and the confidence that momentum should continue in 2017" (2/28/2017)

Who are some of Insulet Corporation's key competitors?

Who are Insulet Corporation's key executives?

Insulet Corporation's management team includes the folowing people:

  • Patrick J. Sullivan, Chairman of the Board, Chief Executive Officer (Age 65)
  • Shacey Petrovic, President, Chief Operating Officer (Age 43)
  • Michael L. Levitz, Chief Financial Officer, Senior Vice President, Treasurer (Age 43)
  • Bradley B. Thomas, Executive Vice President - Human Resources and Organizational Development (Age 59)
  • David Colleran J.D., Senior Vice President, General Counsel, Secretary (Age 45)
  • Aiman Abdel-Malek Ph.D., Senior Vice President - Advanced Technology and Engineering (Age 58)
  • Charles Alpuche, Senior Vice President - Global Manufacturing and Operations (Age 57)
  • Michael Spears, Senior Vice President - Quality and Regulatory Affairs (Age 52)
  • Bret Christensen, Chief Commercial Officer
  • Jessica Hopfield Ph.D., Lead Independent Director (Age 52)

Who owns Insulet Corporation stock?

Insulet Corporation's stock is owned by many different of retail and institutional investors. Top institutional investors include Frontier Capital Management Co. LLC (2.53%), Think Investments LP (1.19%), JPMorgan Chase & Co. (1.05%), Point72 Asset Management L.P. (1.04%), Janus Henderson Group PLC (0.82%) and Bank of New York Mellon Corp (0.50%). Company insiders that own Insulet Corporation stock include Bradley A Thomas, Charles Alpuche, Daniel J Levangie, David A Lemoine, James C Mullen, Jessica Hopfield, Joseph S Zakrzewski, Michael P Spears, Patrick J Sullivan and Regina O Sommer. View Institutional Ownership Trends for Insulet Corporation.

Who sold Insulet Corporation stock? Who is selling Insulet Corporation stock?

Insulet Corporation's stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Think Investments LP, Janus Henderson Group PLC, Nationwide Fund Advisors, Segall Bryant & Hamill LLC, California State Teachers Retirement System, Tributary Capital Management LLC and C WorldWide Group Holding A S. Company insiders that have sold Insulet Corporation company stock in the last year include David A Lemoine, Joseph S Zakrzewski and Regina O Sommer. View Insider Buying and Selling for Insulet Corporation.

Who bought Insulet Corporation stock? Who is buying Insulet Corporation stock?

Insulet Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., JPMorgan Chase & Co., Columbus Circle Investors, Janney Montgomery Scott LLC, EAM Investors LLC, Ameriprise Financial Inc., Macquarie Group Ltd. and Bank of New York Mellon Corp. Company insiders that have bought Insulet Corporation stock in the last two years include Bradley A Thomas, Charles Alpuche, James C Mullen, Jessica Hopfield, Michael P Spears and Patrick J Sullivan. View Insider Buying and Selling for Insulet Corporation.

How do I buy Insulet Corporation stock?

Shares of Insulet Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insulet Corporation's stock price today?

One share of Insulet Corporation stock can currently be purchased for approximately $70.64.

How big of a company is Insulet Corporation?

Insulet Corporation has a market capitalization of $4.21 billion and generates $366.99 million in revenue each year. The medical instruments supplier earns ($28,870,000.00) in net income (profit) each year or ($0.50) on an earnings per share basis. Insulet Corporation employs 640 workers across the globe.

How can I contact Insulet Corporation?

Insulet Corporation's mailing address is 600 Technology Park Dr Ste 200, BILLERICA, MA 01821-4126, United States. The medical instruments supplier can be reached via phone at +1-978-6007000 or via email at ir@insulet.com.


MarketBeat Community Rating for Insulet Corporation (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  751
MarketBeat's community ratings are surveys of what our community members think about Insulet Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Insulet Corporation (NASDAQ:PODD)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 5 Hold Ratings, 10 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $59.77 (15.39% downside)

Consensus Price Target History for Insulet Corporation (NASDAQ:PODD)

Price Target History for Insulet Corporation (NASDAQ:PODD)

Analysts' Ratings History for Insulet Corporation (NASDAQ:PODD)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017Morgan StanleyBoost Price TargetEqual Weight$55.00 -> $63.00N/AView Rating Details
11/3/2017Jefferies Group LLCBoost Price TargetBuy$58.00 -> $67.00N/AView Rating Details
11/3/2017Robert W. BairdBoost Price TargetOutperform$65.00 -> $72.00N/AView Rating Details
11/1/2017Canaccord GenuityUpgradeHold -> Buy$50.00 -> $65.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$65.00 -> $74.00N/AView Rating Details
10/10/2017WedbushReiterated RatingBuy$60.00 -> $65.00N/AView Rating Details
9/15/2017Barclays PLCInitiated CoverageOverweight -> Overweight$65.00LowView Rating Details
8/4/2017Oppenheimer Holdings, Inc.Set Price TargetHold$55.00LowView Rating Details
8/4/2017Northland SecuritiesReiterated RatingBuyLowView Rating Details
8/4/2017Cowen and CompanyReiterated RatingOutperform$52.00 -> $63.00HighView Rating Details
7/17/2017BTIG ResearchDowngradeBuy -> NeutralMediumView Rating Details
5/25/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
5/22/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$47.00LowView Rating Details
5/14/2017B. RileyReiterated RatingNeutral$44.00LowView Rating Details
2/27/2017Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
11/17/2016J P Morgan Chase & CoReiterated RatingHold$38.00N/AView Rating Details
5/16/2016Sterne Agee CRTReiterated RatingNeutralN/AView Rating Details
2/26/2016Benchmark Co.UpgradeHold -> Buy$30.00 -> $40.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Insulet Corporation (NASDAQ:PODD)

Earnings by Quarter for Insulet Corporation (NASDAQ:PODD)

Earnings History by Quarter for Insulet Corporation (NASDAQ PODD)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018        
11/2/2017Q3 2017($0.10)($0.04)$114.02 million$121.80 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.13)($0.13)$106.23 million$110.00 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.16)($0.17)$97.73 million$101.70 millionViewListenView Earnings Details
2/27/2017Q416($0.05)($0.16)$100.61 million$103.58 millionViewListenView Earnings Details
11/3/2016Q316($0.09)($0.05)$89.75 million$94.90 millionViewN/AView Earnings Details
8/3/2016Q216($0.17)($0.08)$81.10 million$87.30 millionViewN/AView Earnings Details
4/28/2016Q116($0.19)($0.19)$79.06 million$81.21 millionViewListenView Earnings Details
2/25/2016Q415($0.26)($0.48)$91.89 million$100.10 millionViewListenView Earnings Details
11/5/2015Q315($0.26)($0.33)$83.56 million$87.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.27)$70.32 million$75.60 millionViewListenView Earnings Details
4/30/2015Q115($0.10)($0.21)$68.20 million$61.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.04)($0.10)$73.52 million$72.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.06)$72.94 million$72.00 millionViewN/AView Earnings Details
5/7/2014Q114($0.06)($0.11)$68.47 million$69.20 millionViewN/AView Earnings Details
2/27/2014Q413($0.09)($0.04)$67.94 million$68.53 millionViewN/AView Earnings Details
11/7/2013Q313($0.16)($0.39)$62.01 million$61.10 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.19)($0.20)$60.47 million$60.09 millionViewN/AView Earnings Details
5/6/2013Q1 2013($0.21)($0.20)$57.26 million$57.40 millionViewN/AView Earnings Details
2/27/2013Q4 2012($0.21)($0.21)$59.12 million$57.80 millionViewN/AView Earnings Details
11/8/2012Q312($0.22)($0.26)$54.93 million$54.80 millionViewN/AView Earnings Details
8/8/2012($0.25)($0.30)ViewN/AView Earnings Details
5/9/2012($0.28)($0.31)ViewN/AView Earnings Details
2/9/2012($0.26)($0.30)ViewN/AView Earnings Details
11/3/2011($0.25)($0.29)ViewN/AView Earnings Details
8/2/2011($0.21)($0.42)ViewN/AView Earnings Details
5/9/2011($0.22)($0.22)ViewN/AView Earnings Details
2/15/2011($0.26)($0.50)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Insulet Corporation (NASDAQ:PODD)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.07)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20178($0.23)($0.10)($0.15)
Q2 20178($0.16)($0.04)($0.12)
Q3 20178($0.13)($0.02)($0.09)
Q4 20178($0.11)($0.02)($0.09)
Q1 20185($0.11)$0.02($0.06)
Q2 20185($0.11)$0.05($0.02)
Q3 20184($0.10)$0.14$0.02
Q4 20184($0.09)$0.06($0.01)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insulet Corporation (NASDAQ:PODD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Insulet Corporation (NASDAQ PODD)

Insider Ownership Percentage: 1.90%
Insider Trades by Quarter for Insulet Corporation (NASDAQ:PODD)
Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)

Insider Trades by Quarter for Insulet Corporation (NASDAQ PODD)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017James C. MullenDirectorBuy2,500$67.45$168,625.00View SEC Filing  
9/6/2017Charles AlpucheEVPBuy2,500$58.08$145,200.00View SEC Filing  
5/16/2017Michael P. SpearsSVPBuy2,500$40.59$101,475.00View SEC Filing  
5/11/2017Bradley A. ThomasEVPBuy3,000$38.69$116,070.00View SEC Filing  
5/11/2017Jessica HopfieldDirectorBuy2,580$38.68$99,794.40View SEC Filing  
5/1/2017David A. LemoineDirectorSell1,524$43.40$66,141.60View SEC Filing  
3/13/2017Regina O. SommerDirectorSell40,000$45.00$1,800,000.00View SEC Filing  
3/6/2017David A. LemoineDirectorSell1,282$45.15$57,882.30View SEC Filing  
3/2/2017Joseph S. ZakrzewskiDirectorSell40,000$46.86$1,874,400.00View SEC Filing  
12/9/2016Charles AlpucheSVPBuy6,600$37.70$248,820.00View SEC Filing  
12/2/2016Patrick J. SullivanCEOBuy40,000$33.89$1,355,600.00View SEC Filing  
12/1/2016Bradley A. ThomasEVPBuy3,100$32.45$100,595.00View SEC Filing  
5/25/2016Regina O SommerDirectorSell8,019$30.42$243,937.98View SEC Filing  
5/18/2016Patrick J SullivanCEOBuy45,000$27.00$1,215,000.00View SEC Filing  
5/13/2016Bradley A ThomasEVPBuy2,975$26.63$79,224.25View SEC Filing  
5/5/2016Bradley A ThomasEVPBuy1,656$30.13$49,895.28View SEC Filing  
3/10/2016Daniel J LevangieInsiderSell12,299$30.89$379,916.11View SEC Filing  
3/7/2016Daniel J LevangieInsiderSell7,663$31.15$238,702.45View SEC Filing  
3/2/2016Jessica HopfieldDirectorBuy3,230$30.91$99,839.30View SEC Filing  
6/5/2015Patrick J SullivanCEOBuy10,000$29.39$293,900.00View SEC Filing  
5/28/2015Patrick J SullivanCEOBuy20,000$27.91$558,200.00View SEC Filing  
5/15/2015Timothy J ScannellDirectorBuy3,500$27.05$94,675.00View SEC Filing  
5/5/2015Bradley A ThomasEVPBuy1,000$27.26$27,260.00View SEC Filing  
5/5/2015Patrick RyanCOOBuy3,669$26.99$99,026.31View SEC Filing  
4/2/2015R Anthony DiehlGeneral CounselSell3,372$30.96$104,397.12View SEC Filing  
3/9/2015Patrick J SullivanCEOBuy10,000$31.93$319,300.00View SEC Filing  
3/2/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
2/12/2015Charles T LiamosDirectorSell4,000$32.00$128,000.00View SEC Filing  
1/2/2015Charles T LiamosDirectorSell4,000$46.08$184,320.00View SEC Filing  
11/3/2014Charles T LiamosDirectorSell4,000$42.95$171,800.00View SEC Filing  
10/1/2014Charles T LiamosDirectorSell4,000$36.58$146,320.00View SEC Filing  
10/1/2014R Anthony DiehlGeneral CounselSell1,250$36.59$45,737.50View SEC Filing  
9/10/2014Charles T LiamosDirectorSell4,000$35.17$140,680.00View SEC Filing  
9/2/2014Duane DesistoCEOSell20,000$36.30$726,000.00View SEC Filing  
8/1/2014Duane DesistoCEOSell20,000$34.23$684,600.00View SEC Filing  
7/1/2014Duane DesistoCEOSell20,000$40.52$810,400.00View SEC Filing  
7/1/2014R Anthony DiehlGeneral CounselSell1,250$39.65$49,562.50View SEC Filing  
6/11/2014R Anthony DiehlGeneral CounselSell17,871$37.09$662,835.39View SEC Filing  
6/9/2014Peter DevlinInsiderSell12,314$37.10$456,849.40View SEC Filing  
4/8/2014Peter DevlinInsiderSell30,000$41.25$1,237,500.00View SEC Filing  
4/3/2014R Anthony DiehlGeneral CounselSell4,617$48.67$224,709.39View SEC Filing  
3/6/2014R Anthony DiehlGeneral CounselSell12,458$49.28$613,930.24View SEC Filing  
3/6/2014Tracey Haas WielinskiVPSell8,275$49.21$407,212.75View SEC Filing  
2/3/2014Charles LiamosDirectorSell11,037$42.93$473,818.41View SEC Filing  
2/3/2014Duane DesistoCEOSell20,000$42.95$859,000.00View SEC Filing  
2/3/2014Peter DevlinInsiderSell30,000$42.82$1,284,600.00View SEC Filing  
1/3/2014Charles LiamosCOOSell86,000$36.02$3,097,720.00View SEC Filing  
1/2/2014Duane DesistoCEOSell20,000$36.07$721,400.00View SEC Filing  
12/3/2013Charles LiamosCOOSell63,808$36.26$2,313,678.08View SEC Filing  
11/18/2013Charles LiamosCOOSell80,000$35.60$2,848,000.00View SEC Filing  
9/3/2013Duane DesistoCEOSell20,000$33.38$667,600.00View SEC Filing  
8/29/2013Sally CrawfordDirectorSell9,000$33.42$300,780.00View SEC Filing  
8/15/2013Regina SommerDirectorSell5,000$33.32$166,600.00View SEC Filing  
8/1/2013Duane DesistoCEOSell20,000$31.85$637,000.00View SEC Filing  
7/1/2013Duane DesistoCEOSell20,000$31.51$630,200.00View SEC Filing  
7/1/2013Peter DevlinInsiderSell30,000$31.48$944,400.00View SEC Filing  
6/14/2013Sally CrawfordDirectorSell31,000$30.47$944,570.00View SEC Filing  
6/10/2013R Anthony DiehlGeneral CounselSell38,455$30.50$1,172,877.50View SEC Filing  
6/3/2013Duane DesistoCEOSell20,000$29.76$595,200.00View SEC Filing  
12/3/2012Brian K RobertsCFOSell10,000$21.92$219,200.00View SEC Filing  
11/1/2012Brian K RobertsCFOSell10,000$21.49$214,900.00View SEC Filing  
9/4/2012Brian K RobertsCFOSell10,000$20.78$207,800.00View SEC Filing  
9/4/2012Duane DesistoCEOSell20,000$20.97$419,400.00View SEC Filing  
9/4/2012Ruthann DepietroVPSell1,000$20.90$20,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Insulet Corporation (NASDAQ PODD)

Source:
DateHeadline
Insulet Corporation (PODD) Expected to Post Earnings of -$0.07 Per ShareInsulet Corporation (PODD) Expected to Post Earnings of -$0.07 Per Share
www.americanbankingnews.com - November 18 at 7:40 AM
Insulet Corporation (PODD) Director Purchases $168,625.00 in StockInsulet Corporation (PODD) Director Purchases $168,625.00 in Stock
www.americanbankingnews.com - November 14 at 8:26 PM
Insulet Corporation to Present at Upcoming Investor ConferenceInsulet Corporation to Present at Upcoming Investor Conference
finance.yahoo.com - November 14 at 6:54 AM
ETFs with exposure to Insulet Corp. : November 13, 2017ETFs with exposure to Insulet Corp. : November 13, 2017
finance.yahoo.com - November 14 at 6:54 AM
Insulet Corporation (PODD) Cut to "Hold" at Zacks Investment ResearchInsulet Corporation (PODD) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM
Insulet Announces Pricing of Convertible Senior Notes Due 2024Insulet Announces Pricing of Convertible Senior Notes Due 2024
finance.yahoo.com - November 9 at 11:46 AM
Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : November 6, 2017Insulet Corp. breached its 50 day moving average in a Bullish Manner : PODD-US : November 6, 2017
finance.yahoo.com - November 7 at 8:55 AM
Insulet Announces Private Offering of Convertible Senior NotesInsulet Announces Private Offering of Convertible Senior Notes
finance.yahoo.com - November 7 at 8:55 AM
Insulet Corp. :PODD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Insulet Corp. :PODD-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 8:55 AM
Insulet Corporation Expected to Post FY2021 Earnings of $1.61 Per Share (PODD)Insulet Corporation Expected to Post FY2021 Earnings of $1.61 Per Share (PODD)
www.americanbankingnews.com - November 6 at 2:22 PM
Q3 2018 EPS Estimates for Insulet Corporation Raised by Analyst (PODD)Q3 2018 EPS Estimates for Insulet Corporation Raised by Analyst (PODD)
www.americanbankingnews.com - November 6 at 12:30 PM
Insulet Co. (PODD) Given Consensus Rating of "Buy" by AnalystsInsulet Co. (PODD) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 9:30 PM
Insulet Corporation (PODD) PT Raised to $72.00 at Robert W. BairdInsulet Corporation (PODD) PT Raised to $72.00 at Robert W. Baird
www.americanbankingnews.com - November 5 at 7:42 AM
Insulet Corporation (PODD) PT Raised to $67.00 at Jefferies Group LLCInsulet Corporation (PODD) PT Raised to $67.00 at Jefferies Group LLC
www.americanbankingnews.com - November 5 at 7:16 AM
Insulet Corporation (PODD) Given New $63.00 Price Target at Morgan StanleyInsulet Corporation (PODD) Given New $63.00 Price Target at Morgan Stanley
www.americanbankingnews.com - November 5 at 7:16 AM
Insulet Reports Third Quarter 2017 Financial ResultsInsulet Reports Third Quarter 2017 Financial Results
www.businesswire.com - November 4 at 9:02 AM
Insulet Corp. (PODD) Has Surged To A New High After Q3 Loss NarrowsInsulet Corp. (PODD) Has Surged To A New High After Q3 Loss Narrows
www.nasdaq.com - November 4 at 9:02 AM
Insulet (PODD) Q3 2017 Results - Earnings Call TranscriptInsulet (PODD) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 4 at 9:02 AM
Here's Why Insulet Corporation's Investors Are PumpedHere's Why Insulet Corporation's Investors Are Pumped
finance.yahoo.com - November 4 at 9:02 AM
Edited Transcript of PODD earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of PODD earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 9:02 AM
Insulet Corporation (PODD) Posts  Earnings Results, Beats Estimates By $0.06 EPSInsulet Corporation (PODD) Posts Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - November 3 at 6:24 PM
Heres Why Insulet Corporations Investors Are PumpedHere's Why Insulet Corporation's Investors Are Pumped
www.fool.com - November 3 at 12:38 PM
Insulet Corporation (Nasdaq: PODD) to Ring The Nasdaq Stock Market Closing BellInsulet Corporation (Nasdaq: PODD) to Ring The Nasdaq Stock Market Closing Bell
feeds.benzinga.com - November 3 at 10:53 AM
Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales
www.fool.com - November 3 at 10:26 AM
Canaccord Genuity Reiterates "Hold" Rating for Insulet Corporation (PODD)Canaccord Genuity Reiterates "Hold" Rating for Insulet Corporation (PODD)
www.americanbankingnews.com - November 1 at 10:24 PM
Insulet Corporation Raises Awareness for Diabetes Community During National Diabetes Awareness MonthInsulet Corporation Raises Awareness for Diabetes Community During National Diabetes Awareness Month
finance.yahoo.com - November 1 at 7:39 AM
Insulet Corporation Raises Awareness for Diabetes Community During National Diabetes Awareness MonthInsulet Corporation Raises Awareness for Diabetes Community During National Diabetes Awareness Month
finance.yahoo.com - November 1 at 7:39 AM
 Brokerages Anticipate Insulet Corporation (PODD) Will Post Quarterly Sales of $114.24 Million Brokerages Anticipate Insulet Corporation (PODD) Will Post Quarterly Sales of $114.24 Million
www.americanbankingnews.com - October 30 at 4:02 AM
Zacks: Brokerages Expect Insulet Corporation (PODD) Will Announce Earnings of -$0.11 Per ShareZacks: Brokerages Expect Insulet Corporation (PODD) Will Announce Earnings of -$0.11 Per Share
www.americanbankingnews.com - October 28 at 5:31 PM
Insulet Corp. breached its 50 day moving average in a Bearish Manner : PODD-US : October 26, 2017Insulet Corp. breached its 50 day moving average in a Bearish Manner : PODD-US : October 26, 2017
finance.yahoo.com - October 27 at 10:58 AM
Insulet Corporation (PODD) Scheduled to Post Earnings on ThursdayInsulet Corporation (PODD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - October 26 at 4:38 AM
Robbins Arroyo LLP: Insulet Corporation (PODD) Misled Shareholders According to a Shareholder Derivative LawsuitRobbins Arroyo LLP: Insulet Corporation (PODD) Misled Shareholders According to a Shareholder Derivative Lawsuit
finance.yahoo.com - October 24 at 8:45 AM
Robbins Arroyo LLP: Insulet Corporation (PODD) Misled Shareholders According to a Shareholder Derivative LawsuitRobbins Arroyo LLP: Insulet Corporation (PODD) Misled Shareholders According to a Shareholder Derivative Lawsuit
finance.yahoo.com - October 24 at 8:45 AM
ETFs with exposure to Insulet Corp. : October 20, 2017ETFs with exposure to Insulet Corp. : October 20, 2017
finance.yahoo.com - October 21 at 8:17 AM
Insulet and Dexcom Partner to Offer Choices for Animas UsersInsulet and Dexcom Partner to Offer Choices for Animas Users
finance.yahoo.com - October 19 at 7:40 AM
Zacks Investment Research Upgrades Insulet Corporation (PODD) to "Hold"Zacks Investment Research Upgrades Insulet Corporation (PODD) to "Hold"
www.americanbankingnews.com - October 15 at 12:16 PM
Insulet Corporation (PODD) Earns Outperform Rating from Leerink SwannInsulet Corporation (PODD) Earns Outperform Rating from Leerink Swann
www.americanbankingnews.com - October 14 at 11:58 PM
Insulet Corporation (PODD) Stock Rating Reaffirmed by Robert W. BairdInsulet Corporation (PODD) Stock Rating Reaffirmed by Robert W. Baird
www.americanbankingnews.com - October 14 at 9:32 PM
Insulet Corporation (PODD) Given Average Recommendation of "Buy" by BrokeragesInsulet Corporation (PODD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - October 12 at 12:48 AM
Insulet Corporation (PODD) Expected to Announce Quarterly Sales of $114.24 MillionInsulet Corporation (PODD) Expected to Announce Quarterly Sales of $114.24 Million
www.americanbankingnews.com - October 11 at 7:36 AM
ETFs with exposure to Insulet Corp. : October 9, 2017ETFs with exposure to Insulet Corp. : October 9, 2017
finance.yahoo.com - October 10 at 1:24 AM
 Brokerages Anticipate Insulet Corporation (PODD) to Announce -$0.11 EPS Brokerages Anticipate Insulet Corporation (PODD) to Announce -$0.11 EPS
www.americanbankingnews.com - October 9 at 12:38 PM
Insulet Corporation (PODD) Rating Lowered to Sell at Zacks Investment ResearchInsulet Corporation (PODD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - October 8 at 12:36 PM
Insulet Shows Rising Price Performance With Jump To 91 RS RatingInsulet Shows Rising Price Performance With Jump To 91 RS Rating
finance.yahoo.com - October 7 at 7:29 AM
Insulet Shows Rising Price Performance With Jump To 91 RS RatingInsulet Shows Rising Price Performance With Jump To 91 RS Rating
finance.yahoo.com - October 7 at 7:29 AM
Insulet Corp. :PODD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Insulet Corp. :PODD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 7:29 AM
Insulet Corp. :PODD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017Insulet Corp. :PODD-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 7:29 AM
Insulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero CostInsulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero Cost
finance.yahoo.com - October 7 at 7:29 AM
Insulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero CostInsulet Offers Welcome Program for Animas® Users to Try Omnipod® Insulin Management System at Zero Cost
finance.yahoo.com - October 7 at 7:29 AM
Insulet Corp. – Value Analysis (NASDAQ:PODD) : October 3, 2017Insulet Corp. – Value Analysis (NASDAQ:PODD) : October 3, 2017
finance.yahoo.com - October 5 at 5:03 PM

Social Media

Financials

Chart

Insulet Corporation (NASDAQ PODD) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.